Additionally, SGLT-2 inhibitors demonstrated a beneficial effect in reducing mortality (RR 0.25; 95% CI 0.06 to 0.98; p = 0.05) and cardiovascular disease (CVD) (RR 0.41; 95% CI 0.17 to 0.98; p = 0.04). Here, SLC5A2 is linked to cardiovascular disorder.